KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Supernus Pharmaceuticals (SUPN) over the last 10 years, with Q3 2025 value amounting to -$2.6 million.

  • Supernus Pharmaceuticals' Deferred Taxes rose 5910.0% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.9 million, marking a year-over-year increase of 5456.21%. This contributed to the annual value of -$20.1 million for FY2024, which is 2169.25% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Deferred Taxes is -$2.6 million, which was up 5910.0% from -$7.2 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Deferred Taxes high stood at $1.6 million for Q3 2021, and its period low was -$13.0 million during Q1 2022.
  • For the 5-year period, Supernus Pharmaceuticals' Deferred Taxes averaged around -$4.8 million, with its median value being -$4.5 million (2021).
  • Its Deferred Taxes has fluctuated over the past 5 years, first surged by 11441.67% in 2021, then crashed by 116022.99% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Deferred Taxes (Quarter) stood at -$4.5 million in 2021, then plummeted by 71.87% to -$7.8 million in 2022, then tumbled by 34.78% to -$10.5 million in 2023, then soared by 99.31% to -$72000.0 in 2024, then plummeted by 3573.61% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$7.2 million for Q2 2025, and -$4.0 million during Q1 2025.